Edition:
United States

CytRx Corp (CYTR.OQ)

CYTR.OQ on NASDAQ Stock Exchange Capital Market

0.73USD
26 May 2017
Change (% chg)

-- (--)
Prev Close
$0.73
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
676,525
52-wk High
$3.27
52-wk Low
$0.37

Latest Key Developments (Source: Significant Developments)

Cytrx reports Q1 loss per share $0.10
Wednesday, 10 May 2017 09:00am EDT 

May 10 (Reuters) - Cytrx Corp :Cytrx reports first quarter 2017 financial results.Q1 loss per share $0.10.Cytrx corp - goal is to submit a rolling nda under section 505(b)(2) to FDA in Q4 of 2017 for aldoxorubicin.Cytrx Corp- commercial launch of aldoxorubicin is projected for 2018 in U.S.Cytrx Corp - Cytrx also plans to discuss with European Medicines Agency a path to filing a marketing authorization application. For aldoxorubicin.  Full Article

Cytrx Corp prices $15 mln public offering of common stock
Friday, 28 Apr 2017 07:51am EDT 

April 28 (Reuters) - Cytrx Corp :Cytrx Corporation announces pricing of $15 million public offering of common stock.Says public offering of 30.0 million common shares priced at $0.50per share.  Full Article

Cytrx says FDA agreement on regulatory pathway for Aldoxorubicin
Wednesday, 19 Apr 2017 07:00am EDT 

April 19 (Reuters) - Cytrx Corp ::Cytrx announces FDA agreement on regulatory pathway to approval for Aldoxorubicin in soft tissue sarcomas.Development program can support approval, no new studies requested.Cytrx is under confidentiality agreements with a number of companies for a commercial partnership for marketing of Aldoxorubicin.NDA submission by Cytrx being prepared.Goal is to submit a rolling NDA to FDA for soft tissue sarcomas in last quarter of 2017.Proposed product label would include treatment of soft tissue sarcomas.Is under confidentiality agreements with a number of companies for a commercial partnership for marketing of Aldoxorubicin.Also plans to discuss with European Medicines Agency a path to filing a marketing authorization application.Commercial launch of Aldoxorubicin is still projected for 2018 in United States.  Full Article

CytRx says files for stock shelf offering of upto $150 mln
Friday, 7 Apr 2017 06:40am EDT 

CytRx Corp :CytRx Corp says files for stock shelf offering of upto $150 million.  Full Article

Cytrx Corp says files for mixed shelf offering of up to $200 mln- SEC filing
Thursday, 22 Dec 2016 02:17pm EST 

Cytrx Corp - :Cytrx Corp says files for mixed shelf offering of up to $200 million - SEC filing.  Full Article

Cytrx presents positive interim results from on-going clinical trial
Friday, 11 Nov 2016 09:00am EST 

Cytrx Corp : Cytrx says dose-limiting toxicities were not observed in either cohort, and no clinically significant cardiac toxicities were seen . Cytrx says there were nine treatment-related serious adverse events, and no treatment-related deaths .Cytrx presents positive interim results from on-going phase 1b/2 aldoxorubicin combination clinical trial at the 2016 ctos annual meeting.  Full Article

Cytrx reports loss per share of $0.27 for Q2 2016
Friday, 29 Jul 2016 09:00am EDT 

Cytrx Corp :Q2 loss per share $0.27.  Full Article

Cytrx Corp announces pricing of $20 mln public offering
Friday, 15 Jul 2016 07:30am EDT 

Cytrx Corp : Cytrx Corp announces pricing of $20 million public offering of common stock and warrants . Priced offering of an aggregate of approximately 28.6 million shares of common stock at a price to public of $0.70 per share .Investors will also receive warrants to purchase up to approximately 28.6 million shares with an exercise price of $0.70 per share.  Full Article

CytRx presents updated Aldoxorubicin trial results
Monday, 6 Jun 2016 09:00am EDT 

CytRx Corp : Cytrx Corp says clinical data presented at asco continues to support safety and activity of aldoxorubicin in multiple high unmet need tumor types .Cytrx presents updated aldoxorubicin clinical trial results at the 2016 american society of clinical oncology annual meeting.  Full Article

Cytrx Corp issued 1.6 mln shares for benefit of claimants of IN RE Cytrx securities litigation
Friday, 27 May 2016 12:35pm EDT 

: Cytrx Corp says on May 25, 2016, issued for benefit of claimants in matter of IN RE Cytrx Securities litigation total of 1.6 million shares of stock . Cytrx Corp says shares were issued pursuant to court's judgment and order granting final approval of previously announced settlement of matter . Cytrx Corp says for purposes of this settlement, the shares were valued at an aggregate of $4.5 million - SEC Filing Source - http://1.usa.gov/1U0Sgqg (Bengaluru Newsroom; +1 646 223 8780).  Full Article

More From Around the Web

BRIEF-Cytrx reports Q1 loss per share $0.10

* Cytrx corp - goal is to submit a rolling nda under section 505(b)(2) to FDA in Q4 of 2017 for aldoxorubicin